SKYE Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Skye Bioscience Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerSKYE

Market Cap27.4M

Cash RunwayRunway < 6 months

Next Catalyst2026-11-20

Public Research Snapshot

Skye Bioscience Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for GLP-1 (Approved).

Pipeline

Asset	Indication	Modality	Stage	Public Note
GLP-1	n/a	n/a	Approved	Public pipeline row
Nimacimab’s Unique Attributes	n/a	n/a	Preclinical	Public pipeline row
Non-Incretin Product Landscape	n/a	n/a	Phase 2	Public pipeline row
Nimacimab injection	Obesity	n/a	Phase 2	Public pipeline row
SBI-100 Ophthalmic Emulsion, 0.5%	Primary Open Angle Glaucoma \| Ocular Hypertension	n/a	Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-11-20	Nimacimab injection	Low
Topline Data	October 2025	n/a	Low
Corporate Update	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT06144918	Phase 2	COMPLETED	56	2024-02-22
NCT06577090	Phase 2	ACTIVE_NOT_RECRUITING	136	2026-11-20

Scientific Context

catalyst_type | Topline Data
catalyst_type | Corporate Update
catalyst_window | October 2025
asset_name | GLP-1
clinical_stage | Approved

Want the full SKYE research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.